Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling (Q39639310)

13 September 2017

title

Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling (English)

1 reference

13 September 2017

1 reference

1 reference

L de Zwart

1

1 reference

13 September 2017

J Snoeys

2

1 reference

13 September 2017

J De Jong

3

1 reference

13 September 2017

J Sukbuntherng

4

1 reference

13 September 2017

E Mannaert

5

1 reference

13 September 2017

M Monshouwer

6

1 reference

13 September 2017

language of work or name

English

0 references

publication date

1 July 2016

1 reference

Clinical Pharmacology & Therapeutics

13 September 2017

published in

1 reference

13 September 2017

volume

100

1 reference

13 September 2017

issue

5

1 reference

13 September 2017

page(s)

548-557

1 reference

Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions

13 September 2017

cites work

1 reference

Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.

21 January 2018

1 reference

Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults

21 January 2018

1 reference

Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants

21 January 2018

1 reference

Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations

21 January 2018

1 reference

Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions

21 January 2018

1 reference

Correlation between the systemic clearance of drugs and their food effects in humans.

21 January 2018

1 reference

The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia

21 January 2018

1 reference

Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance

21 January 2018

1 reference

Use of intrinsic clearance for prediction of human hepatic clearance

21 January 2018

1 reference

Reassessing models of hepatic extraction

21 January 2018

1 reference

Prediction of hepatic clearance in human from in vitro data for successful drug development

21 January 2018

1 reference

Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole

21 January 2018

1 reference

Persistent inhibition of CYP3A4 by ketoconazole in modified Caco-2 cells.

21 January 2018

1 reference

Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole

21 January 2018

1 reference

Pharmacokinetic and Pharmacodynamic Interactions of Oral Midazolam with Ketoconazole, Fluoxetine, Fluvoxamine, and Nefazodone

21 January 2018

1 reference

Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.

21 January 2018

1 reference

Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2.

21 January 2018

1 reference

Comparison of In Vitro and In Vivo Inhibition Potencies of Fluvoxamine toward CYP2C19

21 January 2018

1 reference

Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation

21 January 2018

1 reference

A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.

21 January 2018

1 reference

pH-dependent drug-drug interactions for weak base drugs: potential implications for new drug development

21 January 2018

1 reference

Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on th

21 January 2018

1 reference

Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go?

21 January 2018

1 reference

Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.

21 January 2018

1 reference

Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover.

21 January 2018

1 reference

Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs

21 January 2018

1 reference

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

21 January 2018

1 reference

In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.

21 January 2018

1 reference

Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans

21 January 2018

1 reference

Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use.

21 January 2018

1 reference

Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A

21 January 2018

1 reference

Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam

21 January 2018

1 reference

Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.

21 January 2018

1 reference

Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies

21 January 2018

1 reference

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

21 January 2018

1 reference

Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males

21 January 2018

1 reference

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients

21 January 2018

1 reference

Population pharmacokinetic model of PI-88, a heparanase inhibitor

21 January 2018

1 reference

Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients

21 January 2018

1 reference

Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients.

21 January 2018

1 reference

Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer

21 January 2018

1 reference

Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571.

21 January 2018

1 reference

A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer

21 January 2018

1 reference

Differentiating mucosal and hepatic metabolism of budesonide by local pretreatment with increasing doses of ketoconazole in the proximal jejunum

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CPT.419

1 reference

13 September 2017

1 reference